![]() The Option shall have a 10-year term and shall vest and become exercisable as follows: (i) 25% upon the first anniversary date of your Start Date (the “Initial Vesting Date”) and thereafter (ii) the remaining unvested Options Shares shall vest in 36 equal monthly installments at the close of business on each monthly anniversary of the Initial Vesting Date. The exercise price per Option Share will be equal to closing price per share of the Company’s common stock as reported on the NASDAQ Global Select Market on your Start Date (the “Grant Date”). In the event of a conflict between this Agreement and the Option Agreement, the terms of the Option Agreement shall control. The on-site interview was broken up into 30 minute chunks, with either 1 or 2 team members. Use the CB Insights Platform to explore Kite Pharmas full profile. Phone screen with hiring manager then onsite interview with multiple people on the team. The average salary for QC Specialist - LIMS Administrator at companies like KITE PHARMA in the United States is 262,588 as of July 25, 2023, but the salary range typically falls between 223,969 and 301,207. Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune systems ability to recognize and eradicate tumors. ![]() Such grant shall be evidenced by an option agreement (the “Option Agreement”) to be entered into by and between you and the Company. I interviewed at Kite Pharma (Santa Monica, CA) in Jun 2017. Its lead product candidate is KTE-C19, a chimeric. The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Subject to the approval of the Board of Directors of Kite (the “Board”), or an authorized committee thereof, you shall be granted a stock option (the “Option”) to purchase One Hundred Twenty-Five Thousand (125,000) shares of Kite’s common stock (the “Option Shares”) pursuant to Kite’s 2014 Equity Incentive Plan (the “Plan”). Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |